NCT00245479

A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis

An Open Label, Multi-national Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 802 (actual)
• Sponsor: Ferring Pharmaceuticals · Industry
• Sex: All
• Age: 5 Years – 15 Years
• Healthy volunteers: Accepted

Summary

To evaluate the overall response to desmopressin treatment among previously untreated enuretic children aged 5-15 years after 3 and 6 months of treatment. To investigate the influence of possible predictive factors on response after 3 and 6 months of treatment. To evaluate the proportion of patients achieving dryness. To evaluate the long-term safety profile of oral desmopressin in children with primary nocturnal enuresis.

Detailed description

To evaluate the overall response to desmopressin treatment among previously untreated enuretic children aged 5-15 years after 3 and 6 months of treatment. To investigate the influence of possible predictive factors on response after 3 and 6 months of treatment. To evaluate the proportion of patients achieving dryness. To evaluate the long-term safety profile of oral desmopressin in children with primary nocturnal enuresis.

Conditions

• Nocturnal Enuresis

Interventions

Type	Name	Description
DRUG	Primary nocturnal enuresis	Desmopressin

Timeline

• Start date: 2002-04-01
• Primary completion: 2005-09-01
• Completion: 2006-11-01
• First posted: 2005-10-28
• Last updated: 2011-05-19

Locations

1 site across 1 country: France